Kunshi Biotechnology (Shenzhen) Co., Ltd and Suzhou Puheng Technology Co., Ltd have entered into a strategic partnership to utilize a 3D NAC-Organ technology platform to establish a high-throughput in vitro screening system for CAR-Macrophage cells. The collaboration aims to enhance the research and development (R&D) of new immunotherapies targeting solid tumors. Financial details of the partnership were not disclosed.
Partnership Details
The two companies will leverage their respective technical advantages to use the NAC Solid Tumor platform, a 3D solid tumor cell therapy-specific screening platform developed by Puheng Tech based on NAC Organ in vitro model technology. This platform will be used to efficiently evaluate the tumor targeting, infiltration, and killing capacity of CAR-M cells developed by Kunshi Bio. The NAC Solid Tumor platform integrates multiple immune cells in 3D solid tumor models to establish an immune microenvironment, enabling the creation of solid tumor models of different magnitudes, with up to one million cells. It also provides full-cycle safety and efficacy evaluation services for the development, optimization, and preparation of new CAR-M immune cell platforms.
Future Implications
This strategic partnership positions Kunshi Biotechnology and Puheng Technology at the forefront of innovation in immunotherapy research. By combining their expertise, the companies aim to accelerate the development of novel CAR-Macrophage therapies, potentially offering new treatment options for patients with solid tumors.-Fineline Info & Tech
